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We thank Dr Choi and colleagues for their correspondence and intriguing hypothesis. Unfortunately, we do not have the additional data with which to confidently test the hypothesis stated. We do not have robust osteoporosis data in the Raloxifene Use for the Heart (RUTH) study; we did not systematically measure bone mineral density. In addition, few women (Ͻ10% before data lock) reported osteoporosis as a secondary condition. Approximately 15% reported postbaseline use of bone-active agents. For reported fractures, we did not collect data on whether or not the study participant was osteoporotic. Therefore, with such small numbers, these would not be informative (or even appropriate) subgroup analyses. Although we all believe this is a very interesting hypothesis, we cannot address this question with data from the RUTH trial. 1 
